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Introduction
The hum an CY P2C s ubfamily o f cytochrome P 450 e nzymes co nsists o f four l iver enzymes, CYP2C8, CYP2C9, CYP2C18 and CYP2C19, which metabolize ~20% of all clinically prescribed t herapeutics and a number o f p hysiologically im portant e ndogenous m olecules (Goldstein, 2001) . Among the four CYP2C enzymes, CYP2C8, CYP2C9 and CYP2C19 proteins are mainly expressed in human liver (Goldstein and de Morais, 1994) . CYP2C18 protein has not been identified in any tissue. Low levels of CYP2Cs are also found in extrahepatic tissues such as intestine, lung, kidney and brain (Krishna and Klotz, 1994) . Constitutive expression of CYP2C genes in the liver is believed to be unde r the control of endogenous regulatory signals such as HNF4α (J over et a l., 2 001; K amiyama et a l., 2007), HNF 3γ (B ort et a l., 20 04) and th e CCAAT/enhancer-binding p rotein α (C /EBPα) (Jove r e t a l., 1 998). H owever, e xposure t o numerous structurally unrelated xenobiotics, including rifampicin, hyperforin, phenobarbital, and dexamethasone ( Raucy et al ., 20 02; Ma dan e t al ., 2 003; K omoroski e t al ., 20 04) upregulates CYP2C e nzyme ex pression. I nduction is m ediated v ia upstream r esponsive e lements i n the CYP2C pr omoters f or the xe nobiotic s ensing r eceptors CAR and P XR ( Ferguson e t al ., 200 2; Gerbal-Chaloin et al., 2002; Chen et al., 2003; Chen et al., 2004; Ferguson et al., 2005) . This contributes to in ter-individual v ariability of CY P2C e xpression in h umans a nd af fects the metabolism of c ertain xenobiotics in vivo (Zhou et al., 1990; Williamson et al., 1998; Niemi et al., 2001 ). HNF 4α acts as a central mediator of hepatocyte-specific gene expression and liver function, including control of xenobiotic detoxification, energy metabolism, bile acid synthesis, and serum protein production (Duncan et al., 1994; Stoffel and Duncan, 1997; Li et al., 2000; Hayhurst et al., 2001; Inoue et al., 2002; Kamiya et al., 2003; Tirona et al., 2003) .
Studies in
This article has not been copyedited and formatted. The final version may differ from this version. HNF4α deficient mice (Wiwi and Waxman, 2004) and cultured human hepatocytes (Jover et al., 2001 ) have shown the importance of HNF4α in the constitutive expression of hepatic drugmetabolizing CYP genes. A recent study reported that the level of HNF4α expression in liver accounted for the highest degree of colinearity among the expression of human genes involved in xenobiotic metabolism such as CYP2A6, CYP2B6, CYP2C8, CYP2C9, and CYP2C19. (Wortham et al., 2007) . Analysis of various promoter and enhancer sequences has shown that HNF4α has a positive role in the regulation of numerous rodent and human CYPs (Akiyama and Gonzalez, 2003) . ChIP-on-Chip analysis has demonstrated that HNF4α binds to the regulatory regions of more than 1500 genes including PXR, CYP1A2, CYP2B6, CYP2C8, CYP2D6, and CYP2E1 (Odom et al., 2004) .
Kim and coworkers (Tirona et al., 2003) also demonstrated a role for HNF4α in PXR-and CAR-mediated transactivation of CYP3A4. Chiang and coworkers (Li and Chiang, 2006) concluded that the competition between PXR and HNF4α for their coactivators PGC-1α and SRC-1 contributes an interaction between these receptors. Our laboratory recently reported cross-talk between the proximal HNF4α and the upstream CAR/PXR sites of the CYP2C9 promoter (Chen et al., 2005; Surapureddi et al., 2008) . HNF4α and CAR/PXR synergistically activate the CYP2C9 promoter in HepG2 cells in the presence of the CAR agonist CITCO or PXR agonist rifampicin. Also, mutation of the HNF4α sites nearly abolishes CAR or PXR/rifampicin mediated induction of CYP2C9 in HepG2 cells.
Alt hough HNF4α has been shown to be capable of contributing to CAR/PXR mediated CYP2C9 transcription in HepG2 cells (Chen et al., 2005) , the role of HNF4α in the regulation of CYP2C8 by CAR or P XR has not been addressed due to the unavailability of a n appropriate in vitro cell line. Unlike the CYP2C9 promoter, the CYP2C8 promoter is not upregulated by CAR, This article has not been copyedited and formatted. The final version may differ from this version. , 2005) . W e r ecently us ed c ultured pr imary human hepatocytes to i dentify a P XR/CAR s ite at -8.8 k b w hich a ppeared to be s olely responsible for the induction of CYP2C8 by PXR ligands such as rifampicin as well as the CAR ligand CITCO (Ferguson et al., 2005) . I n the present study, we use primary cultures of hu man hepatocytes to address whether HNF4α sites in the CYP2C8 promoter are also critically involved in the co nstitutive and CAR/PXR-mediated tr anscriptional ac tivation o f CYP2C8. W e fu rther confirmed th e role of t he HNF 4α s ites in th e basal exp ression and ri fampicin-PXR mediated induction of CYP2C9 in primary cultures of hum an hepatocytes. We identified additional new putative HNF4α sites in bo th the CYP2C8 and CYP2C9 promoters a nd showed t hat these b ind
HNF4α in EMSA studies. We mutated each of these HNF4α s ites to determine the ir r elative importance in the u pregulation o f CYP2C8 a nd CYP2C9 i n pr imary hum an he patocytes b y HNF4α and PXR/rifampicin. Finally, we used an adenovirus containing HNF4α-small interfering RNA ( siHNF4) to e xamine the r ole o f H NF4α in both t he co nstitutive an d P XR/rifampicinmediated pr omoter tr ansactivation of the CYP2C p romoters a s w ell a s C YP2C m RNA expression.
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Methods
Promoter constructs and expression plasmids. The pGL3-Basic constructs of wildtype CYP2C8 (-8.9 to -8.5)-3kb, CYP2C9-3kb and the HNF4α site mutants 2C9/150-mut and 2C9/185-mut were described previously (Chen et al., 2004; Ferguson et al., 2005) . Mutation of the new putative HNF4α sites at -181 bp in CYP2C8 (-8.9 to -8.5)-3 kb and -211 bp in CYP2C9-3kb was performed using QuickChange Site-directed mutagenesis (Stratagene, La Jolla, CA). To silence the expression of HNF4α, specific small interfering RNAs (siRNAs) were prepared using an AdEasyTM XL Adenoviral Vector system (Stratagene, CA). siRNA targets for HNF4α were identified using Genscript's target finder. The following sequences were used to silence HNF4α: siHNF4-I @248 bp: 5'-ACATGTACTCCTGCAGATTTA-3'; siHNF4-II @387 Gel Shift Assays. Electrophoretic mobility shift assays were performed as described previously (Chen et al. 2005) . Briefly, Human HNF4α was synthesized in vitro using the TNT In competition experiments, specific cold competitors or a specific antibody to human HNF4α (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were added to the mixture before the addition of proteins. After incubating for 20 min at room temperature, 9.5 μl of the reaction mixture was loaded onto a 5% non-denaturing polyacrylamide gel for electrophoresis in 0.5X TBE buffer for 2 hours at 150V. The gels were dried and exposed to film. The following are the sequences of the oligonucleotides used as probes, wild type or mutated specific cold competitors (hexamer half-sites are indicated by bold capital letters and mutated nucleotides are underlined): Since HNF4α does not activate the CYP2C8 promoter activity in HepG2 cells (Ferguson et al., 2005) , we used primary human hepatocytes in the present study to assess the importance of the two HNF4α binding sites in HNF4 α and PXR-mediated rifampicin upregulation of the CYPC8
CYP2C8-1kb
promoter. We first compared the ability of HNF4α to transactivate the wild type 2C8 (-8.9 to -8.5)-3 kb construct vs. constructs harboring mutations at HNF4α sites at -152 bp (2C8/152-mut),
-181 bp (2C8/181-mut) or both sites (2C8/ HNF4αdmut). Basal activity of the wild-type CYP2C8
reporter constuct was decreased by mutation of each of the HNF4α sites (Fig 3A and B) presumably because the effects of constitutive levels of HNF4α in primary hepatocytes was abolished. The wild type reporter construct was further activated by adenoviral constructs 3A) . Moreover, the double mutation completely abolished HNF4α-mediated transactivation of the CYP2C8 reporter construct.
We then assessed the importance of the two HNF4α binding sites in PXR-mediated rifampicin induction of the CYPC8 promoter. We transfected wild-type 2C8 (-8.9 to -8.5)-3 kb and the three HNF4α mutant constructs (2C8/152-mut), (2C8/181-mut) bp or (2C8/ HNF4αdmut) into primary cultures of human hepatocytes and treated them with 0.2% DMSO or 10 µM rifampicin.
The PXR agonist rifampicin produced a 2-fold increase in actitvity of the wild-type 2C8 (-8.9 to -8.5)-3 kb promoter construct. Rifampicin produced a small but significant increase in luciferase activity for the 2C8/152-mut, while rifampicin upregulation was abolished by the mutation at -181
and by the double mutation (Fig. 3B ). These data indicate that the two HNF4α sites in the CYP2C8 promoter construct play a vital role in PXR/rifampicin-mediated transactivation of CYP2C8 in primary human hepatocytes. expression decreased the basal activity of both the CYP2C8 and 2C9 promoter reporters (48% and 43% respectively), abolished the 2-fold rifampicin-mediated transactivation of the CYP2C8
Role of the different
promoter and decreased the activation of the 2C9 promoter from 2.1-to 1.2-fold (Fig 5) .
Silencing HNF4α resulted in decreased basal and rifampicin-mediated induction of CYP2C-mRNA in primary human hepatocyte cultures. We also examined the effect of siHNF4 on CYP2C mRNA levels in cultured primary human hepatocytes. Cells from four different donors (Table 2) were infected with adenoviruses expressing either siHNF4 or control (scrambled) and treated with 0.2% DMSO or 10 µM rifampicin for 24 h. HNF4 α mRNA was decreased to 31 ± 4% . We observed a variable 4-to 8-fold induction of CYP2C8 mRNA by rifampicin in primary human hepatocytes in different control donors (mean 6.6-fold) (Tables 2   and 3 ). When primary human hepatocytes were treated with siHNF4, the basal expression of CYP2C8 mRNA was down-regulated by ~53%, and the magnitude of induction of CYP2C8 mRNA by rifampicin-mediated was significantly decreased from 6.6-fold to 2.7-fold) (p<0.01)..
Rifampicin also induced CYP2C9 mRNA by 3-fold (Tables 2 and 3 ). Silencing HNF4α decreased the constitutive expression of CYP2C9 by 55% and the magnitude of the induction by rifampicin from 3-fold to 1.5-fold. We also observed a significant (1.8-fold) increase in CYP2C19 mRNA induction in cultured primary hepatocytes but no significant increase in cells treated with siHNF4 (1.1-fold). Because preliminary studies indicated rifampicin produced little or no increase in CYP2C19 promoter activation in primary hepatocytes we were unable to study the effects of mutating the two HNF4 sites on promoter activity. Silencing HNF4 also and -1839 bp (Ferguson et al., 2002; Chen et al., 2005) , respectively. Mutation of these sites abolishes rifampicin induction of the two genes. Our previous studies have also indicated that HNF4α sites are important for the CAR and PXR mediated upregulation of CYP2C9 in HepG2 cells (Chen et al., 2005) . However, these studies did not address the role of HNF4α in CYP2C8 HNF4α binding sites in the CYP2C9 promoter (Chen et al., 2005) and one site in the CYP2C8
promoter (Ferguson et al., 2005) . In the present study, we identified additional HNF4α binding 2007) which reported that adenoviral constructs expressing HNF4α-siRNA had no effect on xenobiotic-mediated induction of CYP2C8 and 2C9 mRNA in cultures of primary hepatocytes.
However, their interpretations were based on the observations that constitutive as well as xenobiotic induced levels of CYP2C8 and CYP2C9 mRNA were decreased by HNF4α-siRNA; subsequently, the magnitude of the induction by PXR/CAR ligands remained unchanged in their hands. We also observed a decrease in constitutive levels of both CYP2C8 and CYP2C9 mRNA; however, our study found a difference in the magnitude of induction by rifampicin when expression of HNF4α was silenced. One difference between the two studies is that we and CYP2C9 genes to PXR agonists and the constitutive levels of these enzymes. This article has not been copyedited and formatted. The final version may differ from this version. 
